AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29968937 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal immunochemical test (FIT) in women with lowered cut-off from 40 to 20 μg Hb/g
Number of subjects: 12383
Study 29968937 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal immunochemical test (FIT) levels for CRC and advanced adenomas (AA)
Number of subjects: 12383
Study 29510001 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab IV doses of 0.1, 0.5, 3 and 10 mg/kg
Number of subjects: 43
Study 29510001 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab SC doses of 50 or 200 mg
Number of subjects: 43
Study 29510001 — intervention group
Group type: COMPARATOR
Intervention: Placebo (IV and SC)
Number of subjects: 43
Study 29510001 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab (IV and SC)
Number of subjects: 43
Study 26975813 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive phototherapy
Number of subjects: 144
Study 26975813 — intervention group
Group type: COMPARATOR
Intervention: Conventional phototherapy
Number of subjects: 144
Study 23793255 — intervention group
Group type: EXPERIMENTAL
Intervention: Music lessons (12 sessions of 75 minutes each)
Number of subjects: 60
Study 23793255 — intervention group
Group type: COMPARATOR
Intervention: No music lessons (control group)
Number of subjects: 60
Study 22176793 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg
Number of subjects: 81
Study 22176793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 21037189 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia frameworks
Number of subjects: 259
Study 21037189 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal frameworks
Number of subjects: 259
Study 21037189 — intervention group
Group type: EXPERIMENTAL
Intervention: Alumina frameworks
Number of subjects: 259
Study 21037189 — intervention group
Group type: EXPERIMENTAL
Intervention: CZR Press veneer ceramics with zirconia frameworks
Number of subjects: 259
Study 21037189 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse interface veneer ceramics with metal frameworks
Number of subjects: 259
Study 21037189 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonleucite-containing veneer ceramics with zirconia frameworks
Number of subjects: 259
Study 21037189 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucite-containing pressed ceramics
Number of subjects: 259
Study 17414240 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-mg fluoxetine
Number of subjects: 411
Study 17414240 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-mg fluoxetine
Number of subjects: 411
Study 17414240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 411
Study 15840751 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic oral contraceptive pill with lower dose of norethisterone
Number of subjects: 23
Study 15840751 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic oral contraceptive pill with higher dose of norethisterone
Number of subjects: 23
Study 12402610 — intervention group
Group type: EXPERIMENTAL
Intervention: Dressing film method (Group A) - exit site cleaned with povidone iodine solution once weekly, covered with gauze, sealed with dressing film
Number of subjects: 442
Study 12402610 — intervention group
Group type: EXPERIMENTAL
Intervention: Dressing film method (Group B) - exit site cleaned with povidone iodine solution once every 2 weeks, covered with gauze, sealed with dressing film
Number of subjects: 442
Study 12402610 — intervention group
Group type: EXPERIMENTAL
Intervention: Dressing film method (Group C) - exit site cleaned with povidone iodine solution once every 3 weeks, covered with gauze, sealed with dressing film
Number of subjects: 442
Study 12402610 — intervention group
Group type: EXPERIMENTAL
Intervention: Dressing film method (Group D) - exit site cleaned with povidone iodine solution once every 4 weeks, covered with gauze, sealed with dressing film
Number of subjects: 442
Study 12402610 — intervention group
Group type: EXPERIMENTAL
Intervention: Dressing film method (Group E) - exit site cleaned with povidone iodine solution once every 5 weeks, covered with gauze, sealed with dressing film
Number of subjects: 442
Study 12402610 — intervention group
Group type: EXPERIMENTAL
Intervention: Dressing film method (Group F) - exit site cleaned with povidone iodine solution once every 6 weeks, covered with gauze, sealed with dressing film
Number of subjects: 442
Study 12402610 — intervention group
Group type: COMPARATOR
Intervention: Control group - exit site cleaned with povidone iodine solution daily, gauze dressing applied
Number of subjects: 442
Study 10465325 — intervention group
Group type: EXPERIMENTAL
Intervention: Education on UTI
Number of subjects: 204
Study 10465325 — intervention group
Group type: COMPARATOR
Intervention: Education on asthma
Number of subjects: 204
Study 7881645 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nebulization of terbutaline (16 mg over 8 hours)
Number of subjects: 16
Study 7881645 — intervention group
Group type: COMPARATOR
Intervention: Intermittent nebulization of terbutaline (4 mg every 2 hours for 20 minutes)
Number of subjects: 16
Study 7881645 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nebulization of terbutaline
Number of subjects: 16
Study 7881645 — intervention group
Group type: COMPARATOR
Intervention: Intermittent nebulization of terbutaline
Number of subjects: 16
Study 7881645 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Continuous and Intermittent nebulization)
Number of subjects: 16
Study 2364920 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental diet (group A, 97 cases)
Number of subjects: 197
Study 2364920 — intervention group
Group type: COMPARATOR
Intervention: Normal diet (group B, 100 cases)
Number of subjects: 197
Study 2364920 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental diet (group A)
Number of subjects: 197
Study 2364920 — intervention group
Group type: COMPARATOR
Intervention: Normal diet (group B)
Number of subjects: 197
Study 417893 — intervention group
Group type: EXPERIMENTAL
Intervention: High pressure oxygen (HPO) with six fractions of 600 rad maximum tissue dose
Number of subjects: 505
Study 417893 — intervention group
Group type: COMPARATOR
Intervention: Air at atmospheric pressure with conventional small fraction daily radiotherapy
Number of subjects: 505
Study 417893 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant high pressure oxygen (HPO) with large fraction radiotherapy
Number of subjects: 505
Study 31846705 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezlotoxumab
Number of subjects: 259
Study 31846705 — intervention group
Group type: COMPARATOR
Intervention: No bezlotoxumab
Number of subjects: 259
Study 31099188 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically-determined BMI
Number of subjects: 384838
Study 31099188 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically-determined femoral neck BMD
Number of subjects: 384838
Study 31099188 — intervention group
Group type: EXPERIMENTAL
Intervention: Low SBP
Number of subjects: 384838
Study 31099188 — intervention group
Group type: COMPARATOR
Intervention: Other metabolic factors and CRP
Number of subjects: 384838
Study 28364091 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment (targeting systolic BP <120 mm Hg)
Number of subjects: 9361
Study 28364091 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure treatment (targeting systolic BP <140 mm Hg)
Number of subjects: 9361
Study 25901092 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium condition (70±29 mmol/d)
Number of subjects: 17
Study 25901092 — intervention group
Group type: COMPARATOR
Intervention: Typical sodium condition (153±29 mmol/d)
Number of subjects: 17
Study 23653366 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port access laparoscopic surgery
Number of subjects: 73
Study 23653366 — intervention group
Group type: COMPARATOR
Intervention: Three-port laparoscopic surgery
Number of subjects: 73
Study 21480207 — intervention group
Group type: EXPERIMENTAL
Intervention: INCB018424 (JAK1 and JAK2 inhibitor)
Number of subjects: 87
Study 21480207 — intervention group
Group type: EXPERIMENTAL
Intervention: Myelofibrosis Symptom Assessment Form
Number of subjects: 87
Study 19238255 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 microg Se/day for 3 months)
Number of subjects: 30
Study 19238255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 17545903 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal decompression (Group 1)
Number of subjects: 44
Study 17545903 — intervention group
Group type: COMPARATOR
Intervention: Decompression and instrumented posterolateral fusion (Group 2)
Number of subjects: 44
Study 17545903 — intervention group
Group type: COMPARATOR
Intervention: Decompression and instrumented posterolateral fusion plus transforaminal interbody fusion (TLIF) (Group 3)
Number of subjects: 44
Study 14736627 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% increase in the regular standing duration
Number of subjects: 26
Study 14736627 — intervention group
Group type: COMPARATOR
Intervention: No increase in the regular standing duration (Control)
Number of subjects: 26
Study 11734429 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (800 microg twice a day)
Number of subjects: 25
Study 11734429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 9413293 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (13 to 15 mg/kg daily)
Number of subjects: 180
Study 9413293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 8035590 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine (60 mg)
Number of subjects: 10
Study 8035590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3552029 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactitol
Number of subjects: 21
Study 3552029 — intervention group
Group type: COMPARATOR
Intervention: Sorbitol
Number of subjects: 21
Study 3552029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 31638477 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term aerobic exercise program (12 weeks)
Number of subjects: 63
Study 31638477 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physical exercise)
Number of subjects: 63
Study 31147684 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric modulated arc therapy (VMAT) for GYN, rectal, H&N, and prostate cancer
Number of subjects: 344
Study 31147684 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric modulated arc therapy (VMAT) for prostate cancer
Number of subjects: 344
Study 28814394 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean/low-carbohydrate (MED/LC) diet plus 28 g walnuts/d
Number of subjects: 80
Study 28814394 — intervention group
Group type: COMPARATOR
Intervention: Low-fat (LF) diet
Number of subjects: 80
Study 26094328 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential current (IFC)
Number of subjects: 60
Study 26094328 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 60
Study 23395779 — intervention group
Group type: EXPERIMENTAL
Intervention: 250ml beetroot juice daily (active)
Number of subjects: 27
Study 23395779 — intervention group
Group type: COMPARATOR
Intervention: 250ml nitrate-depleted beetroot juice (placebo)
Number of subjects: 27
Study 21214895 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele‐health supported Community COPD Service (two home visits with a specialist COPD clinician and daily tele‐monitoring over eight weeks)
Number of subjects: 60
Study 21214895 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (six home visits by specialist COPD clinicians over eight weeks)
Number of subjects: 60
Study 19172536 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of 17beta-estradiol (E(2) group)
Number of subjects: 60
Study 19172536 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo group)
Number of subjects: 60
Study 17175485 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetoscopic laser therapy
Number of subjects: 0
Study 17175485 — intervention group
Group type: COMPARATOR
Intervention: Amnioreduction
Number of subjects: 0
Study 12653877 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 75 mg daily
Number of subjects: 18790
Study 12653877 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering (target groups < or =90, < or =85, < or =80 mmHg)
Number of subjects: 18790
Study 12653877 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 18790
Study 12653877 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with diabetes
Number of subjects: 18790
Study 12653877 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of avoiding a major CV event
Number of subjects: 18790
Study 12653877 — intervention group
Group type: EXPERIMENTAL
Intervention: Base case analysis
Number of subjects: 18790
Study 12653877 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analysis
Number of subjects: 18790
Study 10740633 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose CDDP plus 5-FU regimen
Number of subjects: 321
Study 10740633 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy group (MMC and UFT)
Number of subjects: 321
Study 8776549 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiperspective Multidimensional Pain Assessment Protocol (MMPAP)
Number of subjects: 651
Study 8776549 — intervention group
Group type: EXPERIMENTAL
Intervention: MMPAP
Number of subjects: 651
Study 1732307 — intervention group
Group type: EXPERIMENTAL
Intervention: Waxed dental floss with greater tensile strength
Number of subjects: 20
Study 1732307 — intervention group
Group type: COMPARATOR
Intervention: Waxed dental floss with lower tensile strength
Number of subjects: 20
Study 6685628 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of [3H]‐dibromodulcitol (400 mg/m2)
Number of subjects: 10
Study 6685628 — intervention group
Group type: EXPERIMENTAL
Intervention: Three smaller daily oral doses of [3H]‐dibromodulcitol (150‐180 mg/m2)
Number of subjects: 10
Study 6685628 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) concentration of [3H]‐dibromodulcitol
Number of subjects: 10
Study 6685628 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma concentration of [3H]‐dibromodulcitol
Number of subjects: 10
Study 6685628 — intervention group
Group type: EXPERIMENTAL
Intervention: Elimination half-life of [3H]‐dibromodulcitol from tissues
Number of subjects: 10
Study 30934035 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert surgeon group
Number of subjects: 20
Study 30934035 — intervention group
Group type: COMPARATOR
Intervention: Novice surgeon group
Number of subjects: 20
Study 30934035 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 29894926 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous saline irrigation
Number of subjects: 185
Study 29894926 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 185
Study 25428583 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg rosuvastatin
Number of subjects: 1390
Study 25428583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1390
Study 25428583 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum endostatin
Number of subjects: 1390
Study 23918843 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise training (AET; n = 60)
Number of subjects: 122
Study 23918843 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC; n = 62)
Number of subjects: 122
Study 23918843 — intervention group
Group type: COMPARATOR
Intervention: Usual care participants who completed the 4-week posttrial exercise program
Number of subjects: 122
Study 20681818 — intervention group
Group type: EXPERIMENTAL
Intervention: Microspheres
Number of subjects: 30
Study 20681818 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel
Number of subjects: 30
Study 20681818 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 19786378 — intervention group
Group type: EXPERIMENTAL
Intervention: Nattokinase combined with red yeast rice (RYR) extract (300 mg of extract/capsule)
Number of subjects: 47
Study 19786378 — intervention group
Group type: EXPERIMENTAL
Intervention: Nattokinase mono formula (50 mg/capsule)
Number of subjects: 47
Study 19786378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 17079111 — intervention group
Group type: COMPARATOR
Intervention: MDRS total score
Number of subjects: 54
Study 17079111 — intervention group
Group type: COMPARATOR
Intervention: MDRS Memory subscale
Number of subjects: 54
Study 17079111 — intervention group
Group type: COMPARATOR
Intervention: MMSE
Number of subjects: 54
Study 17079111 — intervention group
Group type: COMPARATOR
Intervention: MDRS total, Memory subscale, MMSE
Number of subjects: 54
Study 15577134 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 7478
Study 11375838 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled IV meperidine (50 mg/h or more)
Number of subjects: 259
Study 11375838 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled IV meperidine (<50 mg/h)
Number of subjects: 259
Study 8215265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (75 mg/kg for children, 4 g for adults) for 5 days
Number of subjects: 59
Study 8215265 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol (60 mg/kg/day until defervescence, then 40 mg/kg/day) for 14 days
Number of subjects: 59
Study 8215265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 59
Study 8215265 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 59
Study 3114803 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine (12.5 mg, 25 mg)
Number of subjects: 12
Study 3114803 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine (30 mg)
Number of subjects: 12
Study 3114803 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (0.6 mg)
Number of subjects: 12
Study 3114803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29168052 — intervention group
Group type: EXPERIMENTAL
Intervention: WL + AT
Number of subjects: 249
Study 29168052 — intervention group
Group type: EXPERIMENTAL
Intervention: WL + RT
Number of subjects: 249
Study 29168052 — intervention group
Group type: COMPARATOR
Intervention: WL
Number of subjects: 249
Study 26282492 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation via intrathecal route
Number of subjects: 21
Study 26282492 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation via intralesional route
Number of subjects: 21
Study 26282492 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 21
Study 25624389 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (5 μg/kg per day, divided into 8 doses, with possible dose escalation to maximum of 12 μg/kg per day)
Number of subjects: 31
Study 25624389 — intervention group
Group type: COMPARATOR
Intervention: Morphine (0.4 mg/kg per day, with possible dose escalation to maximum of 1 mg/kg per day)
Number of subjects: 31
Study 23438268 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing peers' Facebook photos (experimental group)
Number of subjects: 0
Study 23438268 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing sexually suggestive Facebook photos (Study 2 experimental group)
Number of subjects: 0
Study 23438268 — intervention group
Group type: COMPARATOR
Intervention: Viewing nonsexually suggestive Facebook photos (Study 2 control group)
Number of subjects: 0
Study 20873903 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 205
Study 20873903 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help based on cognitive behavioral therapy (CBTgsh)
Number of subjects: 205
Study 20873903 — intervention group
Group type: COMPARATOR
Intervention: Behavioral weight loss (BWL)
Number of subjects: 205
Study 18258639 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (792 mg/d)
Number of subjects: 96
Study 18258639 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study 16377385 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol, 100 to 300 mg/d
Number of subjects: 54
Study 16377385 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 54
Study 16377385 — intervention group
Group type: COMPARATOR
Intervention: Usual therapy (Control)
Number of subjects: 54
Study 12796516 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0
Study 12796516 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 0
Study 12796516 — intervention group
Group type: COMPARATOR
Intervention: Vigabatrin
Number of subjects: 0
Study 12796516 — intervention group
Group type: COMPARATOR
Intervention: Remacemide
Number of subjects: 0
Study 12796516 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 0
Study 12796516 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 0
Study 10758361 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopy (Group A)
Number of subjects: 30
Study 10758361 — intervention group
Group type: COMPARATOR
Intervention: Blind placement (Group B)
Number of subjects: 30
Study 9264767 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprorelin 11.25 mg every three months
Number of subjects: 44
Study 9264767 — intervention group
Group type: COMPARATOR
Intervention: Leuprorelin 3.75 mg monthly
Number of subjects: 44
Study 9264767 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 44
Study 7886558 — intervention group
Group type: EXPERIMENTAL
Intervention: SK therapy
Number of subjects: 55
Study 7886558 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA therapy
Number of subjects: 55
Study 7886558 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 55
Study 2429076 — intervention group
Group type: EXPERIMENTAL
Intervention: tibalosine 150 mg daily for 1 week
Number of subjects: 12
Study 2429076 — intervention group
Group type: COMPARATOR
Intervention: naloxone (opioid receptor antagonist)
Number of subjects: 12
Study 30134331 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17983 and lactulose
Number of subjects: 33